Skip to main content

Atossa Therapeutics, Inc.

ATOS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001488039

No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Atossa Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of ATOS: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders9392−1
Shares31.1M39.3M+8.24M (+26.5%)
Value$102.1M$63.3M−$38.8M (−38.0%)

New holders (20)

Institutions that held Atossa Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to ATOS in Q4 2021
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC1,170,340$1.87M0.00%
Qube Research & Technologies Ltd287,989$461.0K0.00%
Alps Advisors Inc146,542$234.0K0.00%
National Bank of Canada131,100$210.0K0.00%
Graham Capital Management, L.P.73,105$116.0K0.01%
Wells Fargo & Company65,652$105.0K0.00%
Engineers Gate Manager LP60,809$97.0K0.00%
ETF Managers Group, LLC38,452$64.0K0.00%
Squarepoint Ops LLC27,522$44.0K0.00%
Cutler Group LP24,190$38.0K0.00%
QCM Cayman, Ltd.22,301$36.0K0.22%
XTX Topco Ltd17,275$28.0K0.02%
Credit Suisse AG15,269$24.0K0.00%
Belvedere Trading LLC11,518$15.0K0.00%
Dark Forest Capital Management LP3,512$6.00K0.00%
TD Waterhouse Canada Inc.700$1.20K0.00%
Evoke Wealth, LLC775$1.00K0.00%
Richwood Investment Advisors, LLC600$1.00K0.00%
Snowden Capital Advisors LLC300$00.00%
Castleview Partners, LLC800––

Sold out (21)

Institutions that held Atossa Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.